skinny.

Latest / Eyewire News: The Podcast

Eylea HD Approved for RVO and Extended Dosing

Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.